Though rare, high rates of BRAF p.V600E hotspot mutation (33.3–82%) have enticed growing interest for BRAF-targeting, as ameloblastoma often requires extensive facial surgeries, compromising quality-of-life, yet, frequently recurs64–68. This evidence concerns the gene BRAF and ameloblastoma.